Arterial chemoembolization with cisplatin microcapsules

Okamoto, Yoshitaka; Konno, Akiyoshi; Togawa, Kiyoshi; Kato, Takumi; Tamakawa, Yoshiharu; Amano, Yasuji

doi:10.1038/bjc.1986.61

Cited by 33 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total leukocyte count of cisplatin as well as niosomal cisplatin treated group on day 15 showed significant reduction in number of leukocytes by 34.12% and 15.72 % respectively (Table a b c 3) when compared to their initial blood cell count of day 0 (the day 0 leukocyte count acts here as a self control). As far as the weight of the animals is concerned, in control group, 13.04% weight gain was observed on day 15, and 6.075% weight gain was observed in empty niosomes treated group as compared to their initial weights ( Table 4).…”

Section: Effect Of Drug Treatment On Total Leukocyte Count and The Wementioning

confidence: 87%

Effects of Niosomal Cisplatin and Combination of the Same with Theophylline and with Activated Macrophages in Murine B16F10 Melanoma Model

Gude¹,

Jadhav

Rao³

et al. 2002

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

The use of cisplatin is limited due to its certain toxic effects. In the present study niosomes of cisplatin by using span 60 and cholesterol were prepared and investigated for antimetastatic activity in experimental metastatic model of B16F10 melanoma. Theophylline and its combination effect with free cisplatin and niosomal cisplatin were also carried out in the same model. The effect of treatment with activated macrophages alone and in combination with cisplatin, theophylline and niosomal cisplatin was also observed. Treatment with niosomal cisplatin (1 mg/kg) and combination of the same with theophylline (15 mg/kg) showed significant reduction in the number of lung nodules as compared to untreated control as well as with free cisplatin (1 mg/kg). The treatment with activated macrophages (activated by using Muramyl dipeptide) significantly reduced the secondary growth of tumor in lung. Niosomal cisplatin showed a significant protection against weight loss and bone marrow toxicity as compared to free cisplatin. These results suggest that cisplatin encapsulated in niosomes has significant antimetastatic activity and reduced toxicities than that of free cisplatin. However theophylline failed to show antimetastatic effect alone or in combination with cisplatin or with activated macrophages.

show abstract

Section: Effect Of Drug Treatment On Total Leukocyte Count and The Wementioning

confidence: 87%

Effects of Niosomal Cisplatin and Combination of the Same with Theophylline and with Activated Macrophages in Murine B16F10 Melanoma Model

Gude¹,

Jadhav

Rao³

et al. 2002

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

“…These are the reasons why chemoembolization was used rarely in the past. According to the body of literature, only 54 head and neck SCC patients were treated using embolization protocols in Japan and China in a period of more than 14 years (Okamoto et al, 1985(Okamoto et al, , 1986Kato et al, 1996;Tomura et al, 1996;Konno et al, 1998;Tomura et al, 1998;Li et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin

Kovács

Obitz

2002

Br J Cancer

View full text Add to dashboard Cite

Intensification of intra-arterial chemotherapy with high-dose cisplatin and concomitant reduction of toxicity under the conditions of the head and neck was aimed at by combination of antineoplastic activity and embolizing effect in the same pharmacon. A cisplatin suspension in normal saline (5 mg in 1 ml) with precipitation of microembolizing cisplatin crystals was prepared. No additional pharmacons. Cisplatin dosage was 150 mg m 72 , maximum absolute dose 300 mg, maximum amount of fluid 60 ml. Thirty patients (UICC-Classification of tumours: I/2 patients, II/6, III/2; IV/20) were treated in a neoadjuvant setting with superselective chemoembolization using the cisplatin suspension. A control group (n=30) with the same tumour and nodal staging was treated with a usual cisplatin solution (150 mg m 72 dissolved in 500 ml saline). In both groups, parallel intravenous infusion of sodium thiosulphate (9 g m 72 ). Endpoints were toxicity and response. Continuation of treatment by surgery or radiation. Overall remission was 70% in the study group and 46.7% in the control group after one cycle respectively. Systemic side-effects were very low (grade I WHO) in both groups. Side-effects were found to be similar to post-embolization syndrome (swelling, mild to moderate pain, leucocytosis without fever) in the study group. Chemoembolization in the head and neck area can be carried out routinely using this method.

show abstract

“…Firstly, cytotoxic drugs have been co-administered with biodegradable microspheres which temporarily slow hepatic arterial blood-flow in the tumourbearing liver and increase uptake of drug by the cells (Dakhil et al, 1982;Thom et al, 1989). Secondly, anti-cancer agents, including Adriamycin, mitomycin C, 5 fluorouracil, cis-platin and cytocidal radio-nuclides have been loaded into particles which act as controlled release vehicles in the target tissue Fujimoto et al, 1985;Okamoto et al, 1986;Herba et al, 1988).…”

Section: Discussionmentioning

confidence: 99%

Arteriovenous shunting in patients with colorectal liver metastases

Goldberg

Thomson²,

McCurrach³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

SummaryThe outlook for patients with colorectal liver metastases is poor. Microspheres have been combined with cytotoxics and administered via the hepatic artery in an attempt to improve tumour drug exposure within the liver. However, it has been suggested that arteriovenous connections might occur in association with intrahepatic tumours causing loss of regional advantage, and that the administration of microspheres further exacerbates arteriovenous shunting. In seven patients with colorectal liver metastases, base-line shunting was measured using a tracer quantity of radio-labelled albumin microspheres. The shunted fraction of a 'therapeutic quantity' of microspheres was subsequently measured in the same group of patients using albumin microspheres carrying a different radio-label. Base-line shunt for 0.5 x 106 microspheres was found to be 2.2 ± 1.8% (mean ± s.d.); the percentage shunt of a therapeutic quantity (40 -80 x 106) of microspheres was 3.0±0.8%. We conclude that arteriovenous shunting in patients with colorectal liver metastases is minimal, and is not significantly increased by the administration of therapeutic quantity of microspheres during regional chemotherapy.Conventional treatment of colorectal liver metastases has yielded disappointing results, and attention has turned to hepatic arterial chemotherapy. The potential advantages of regional therapy over systemic drug administration are that high drug levels can be achieved in the tumour-bearing organ and that systemic drug concentrations fall when the drug is retained within the organ, thereby minimising toxicity.Particle-bound regional chemotherapy has been used in an attempt to improve drug uptake by the target organ. There are two mechanisms of value. Firstly, cytotoxic drugs have been co-administered with biodegradable microspheres which temporarily slow hepatic arterial blood-flow in the tumourbearing liver and increase uptake of drug by the cells (Dakhil et al., 1982;Thom et al., 1989). Secondly, anti-cancer agents, including Adriamycin, mitomycin C, 5 fluorouracil, cis-platin and cytocidal radio-nuclides have been loaded into particles which act as controlled release vehicles in the target tissue Fujimoto et al., 1985;Okamoto et al., 1986;Herba et al., 1988).If, however, arteriovenous shunting were associated with liver metastases (Zeissman et al., 1983), a proportion of arterially administered drug would bypass vascular beds in the tumour-bearing liver and be carried to the lungs. The effect would be to reduce tumour drug exposure, increase systemic side-effects and in the case of some particle-bound cytotoxics, increase pulmonary toxicity.With both approaches for enhancing regional therapy, relatively large numbers of particles may be required, either because of the relatively low drug pay-loads associated with some cytotoxic-loaded microspheres, or in order to optimise the arrest of arterial blood-flow. Unfortunately, there have been reports that very high levels of shunting occur when large numbers of microspheres are injected into th...

show abstract

Arterial chemoembolization with cisplatin microcapsules

Cited by 33 publications

References 8 publications

Effects of Niosomal Cisplatin and Combination of the Same with Theophylline and with Activated Macrophages in Murine B16F10 Melanoma Model

Effects of Niosomal Cisplatin and Combination of the Same with Theophylline and with Activated Macrophages in Murine B16F10 Melanoma Model

Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin

Arteriovenous shunting in patients with colorectal liver metastases

Contact Info

Product

Resources

About